CY1124241T1 - Ανοσορρυθμιστες ρετ-απεικονισης - Google Patents

Ανοσορρυθμιστες ρετ-απεικονισης

Info

Publication number
CY1124241T1
CY1124241T1 CY20211100375T CY211100375T CY1124241T1 CY 1124241 T1 CY1124241 T1 CY 1124241T1 CY 20211100375 T CY20211100375 T CY 20211100375T CY 211100375 T CY211100375 T CY 211100375T CY 1124241 T1 CY1124241 T1 CY 1124241T1
Authority
CY
Cyprus
Prior art keywords
imaging
immunogulators
millimolecuies
labeled
synthesis
Prior art date
Application number
CY20211100375T
Other languages
Greek (el)
English (en)
Inventor
David J. Donnelly
Kenneth M. Boy
Yunhui Zhang
Joonyoung Kim
Adrienne PENA
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1124241T1 publication Critical patent/CY1124241T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computed tomography [CT]
    • A61B6/037Emission tomography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12Arrangements for detecting or locating foreign bodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20211100375T 2016-05-19 2021-04-29 Ανοσορρυθμιστες ρετ-απεικονισης CY1124241T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
CY1124241T1 true CY1124241T1 (el) 2022-07-22

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100375T CY1124241T1 (el) 2016-05-19 2021-04-29 Ανοσορρυθμιστες ρετ-απεικονισης

Country Status (25)

Country Link
US (2) US11103605B2 (cg-RX-API-DMAC7.html)
EP (2) EP3827849A1 (cg-RX-API-DMAC7.html)
JP (1) JP6953444B2 (cg-RX-API-DMAC7.html)
KR (1) KR102378288B1 (cg-RX-API-DMAC7.html)
CN (1) CN109414514B (cg-RX-API-DMAC7.html)
AU (1) AU2017268291B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018073642A2 (cg-RX-API-DMAC7.html)
CA (1) CA3024844A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124241T1 (cg-RX-API-DMAC7.html)
DK (1) DK3458111T3 (cg-RX-API-DMAC7.html)
EA (1) EA038019B1 (cg-RX-API-DMAC7.html)
ES (1) ES2864091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210644T8 (cg-RX-API-DMAC7.html)
HU (1) HUE054306T2 (cg-RX-API-DMAC7.html)
IL (1) IL262962B (cg-RX-API-DMAC7.html)
LT (1) LT3458111T (cg-RX-API-DMAC7.html)
MA (1) MA53402A (cg-RX-API-DMAC7.html)
MX (1) MX2018014028A (cg-RX-API-DMAC7.html)
PL (1) PL3458111T3 (cg-RX-API-DMAC7.html)
PT (1) PT3458111T (cg-RX-API-DMAC7.html)
RS (1) RS61742B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810177VA (cg-RX-API-DMAC7.html)
SI (1) SI3458111T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100238T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017201111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
EP3558395A4 (en) 2016-12-23 2020-08-12 The Johns Hopkins University IMAGING OF TUMOR CELLS AND IMMUNE CELLS BASED ON PD-L1 EXPRESSION
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
CN114929728A (zh) 2020-01-06 2022-08-19 百时美施贵宝公司 免疫调节剂
EP4121442A1 (en) * 2020-03-16 2023-01-25 Bristol-Myers Squibb Company Immunomodulators
WO2021202501A1 (en) 2020-03-30 2021-10-07 Bristol-Myers Squibb Company Immunomodulators
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
EP4634205A2 (en) * 2022-12-12 2025-10-22 Merck Sharp & Dohme LLC Cyclic peptides as pet imaging agents of granzyme b

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
ATE380038T1 (de) 1996-07-12 2007-12-15 Immunomedics Inc Radiometall-bindende peptide analoge
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
CA2302360C (en) 1997-09-03 2005-11-15 Immunomedics, Inc. Fluorination of proteins and peptides for f-18 positron emission tomography
US9090668B2 (en) 2007-03-26 2015-07-28 The University Of Tokyo Process for synthesizing cyclic peptide compound
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
US10195578B2 (en) 2010-12-03 2019-02-05 The University Of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
MX2014011353A (es) 2012-03-29 2014-12-05 Aurigene Discovery Tech Ltd Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana.
MX355396B (es) 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo pH依存的に標的分子に結合するペプチドのスクリーニング方法
MY176706A (en) 2013-03-15 2020-08-19 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
HUE039012T2 (hu) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd Gyûrûs peptidomimetikus vegyületek, mint immunomodulátorok
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EA037590B1 (ru) * 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
CA2968961A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
PT3458111T (pt) 2021-04-09
KR20190009330A (ko) 2019-01-28
EP3458111B1 (en) 2021-03-03
AU2017268291B2 (en) 2022-09-29
SG11201810177VA (en) 2018-12-28
IL262962A (en) 2018-12-31
EA201892635A1 (ru) 2019-04-30
JP6953444B2 (ja) 2021-10-27
WO2017201111A1 (en) 2017-11-23
AU2017268291A1 (en) 2019-01-17
RS61742B1 (sr) 2021-05-31
SI3458111T1 (sl) 2021-07-30
EP3458111A1 (en) 2019-03-27
EA038019B1 (ru) 2021-06-23
HRP20210644T1 (hr) 2021-05-28
MX2018014028A (es) 2019-04-04
BR112018073642A2 (pt) 2019-02-26
SMT202100238T1 (it) 2021-05-07
CN109414514B (zh) 2022-03-11
CA3024844A1 (en) 2017-11-23
HUE054306T2 (hu) 2021-08-30
JP2019520328A (ja) 2019-07-18
HRP20210644T8 (hr) 2021-06-25
US20190117801A1 (en) 2019-04-25
MA53402A (fr) 2021-06-02
PL3458111T3 (pl) 2021-06-28
ES2864091T3 (es) 2021-10-13
DK3458111T3 (da) 2021-04-26
US11103605B2 (en) 2021-08-31
KR102378288B1 (ko) 2022-03-23
IL262962B (en) 2020-04-30
EP3827849A1 (en) 2021-06-02
LT3458111T (lt) 2021-05-25
US20210386876A1 (en) 2021-12-16
CN109414514A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
CY1124241T1 (el) Ανοσορρυθμιστες ρετ-απεικονισης
IL273789A (en) Machine learning based system for identifying and monitoring neurological disorders
EP3405574A4 (en) VARIANTS-BASED SICKNESS DIAGNOSTICS AND PURSUIT
EP3482201A4 (en) EARLY DIAGNOSIS OF INFECTIONS
MX385081B (es) Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
EP3436600C0 (en) NON-INVASIVE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER STEATOSIS
EP3408389A4 (en) ISOTACHOPHORESIS FOR PURIFYING NUCLEIC ACIDS
EP3414327A4 (en) PROOF OF NUCLEIC ACIDS
EP3589927A4 (en) MICROTUBE SENSOR FOR PHYSIOLOGICAL MONITORING
MX2017006663A (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
EP3283882A4 (en) BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY AGAINST PD-1 ANTAGONISTS
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
EP3609393C0 (en) NON-INVASIVE BLOOD PRESSURE MEASUREMENT
EP3723692A4 (en) MEDICAL ASSISTANT
EP3458123A4 (en) DYNAMIC CATHETER TOP LOCATION
EP3542159A4 (en) QUANTIFICATION OF EXOSOME SUB-POPULATIONS AND DIAGNOSIS OF NEURODEGENERATIVE DISORDERS
MA49393A (fr) Poly(phosphoesters) destinés à l'administration d'acides nucléiques
HUE059387T2 (hu) Parkinson-kór kezelése
EP3531991C0 (en) WHOLE BODY HYPERTHERMIA SYSTEM
EP3479770A4 (en) ULTRASOUND ENDOSCOPE
EP3603687A4 (en) MEDICAL DEVICE
EP3267987A4 (en) CHEMICALLY MODIFIED CLUROMES FOR USE IN THE PREPARATION OF LIPOXINES
EP3448236A4 (en) OPTICAL COHERENCE TOMOGRAPHY FOR IDENTITY VERIFICATION
EP3479773A4 (en) ULTRASOUND ENDOSCOPE
EP3642643A4 (en) SOUND SOURCE DISTANCE ESTIMATION